Anti‐PD1‐induced psoriasis: a study of 21 patients

Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition

“…Trials of idelalisib with CD‐20 monoclonal antibodies have found an increased number of AEs compared with idelalisib monotherapy, thus ofatumumab may have worsened the cutaneous findings. The delay of 6–20 weeks from drug introduction to development of cutaneous symptoms and the slow resolution over weeks to months after drug discontinuation is consistent with findings seen for programmed cell death‐1 inhibitor‐induced psoriasis, another example of a dermatological immune‐related AE due to unregulated T‐cell activation …”

“…The delay of 6-20 weeks from drug introduction to development of cutaneous symptoms and the slow resolution over weeks to months after drug discontinuation is consistent with findings seen for programmed cell death-1 inhibitor-induced psoriasis, another example of a dermatological immune-related AE due to unregulated T-cell activation. 16 The skin problems in our patients responded to oral acitretin, short courses of oral prednisone, topical steroids and topical retinoids. All patients required discontinuation of PI3K inhibition.…”

Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review

“…Indeed, some cases describe good results with topical treatment with corticoids and vitamin D analogues [12, 13, 14, 15]. However, in several cases local treatment was insufficient with need for oral prednisolone [2, 16, 17], acitretin (vitamin A derivate), or phototherapy [2, 16, 18, 19]. One patient with concomitant psoriasis arthritis was also treated with oral methotrexate [20].…”

“…Twelve individual cases were described. Two authors published a collection of 17 and 5 cases, respectively, in 1 publication [2, 3]. Two additional publications also reported on psoriasis exacerbation but were not included in the tables because detailed information is missing [4, 5].…”

Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease

“…While concurrent treatment with anti‐PD‐L1 therapy may have contributed to the rash in case 2, anti‐PD‐L1 agents have not been strongly linked to neutrophilic dermatoses, with rare reports of Sweet syndrome associated with ipilimumab, another class of checkpoint inhibitors targeting cytotoxic T‐lymphocyte‐associated protein 4 . In addition, neutrophilic recruitment to the skin may occur with immune checkpoint inhibitors as observed in psoriasiform‐like and leukocytoclastic‐vasculitis‐like immune‐related adverse events . Both patients were able to continue treatment with DNMTi but required systemic corticosteroids due to persistently symptomatic skin disease.…”